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Management of Anthracycline Extravasation Injuries 
David Reeves 
 
Abstract 
OBJECTIVE: To review the evidence for the management of anthracycline extravasation and determine 
the optimal treatment of such injuries.  
DATA SOURCES: A search of MEDLINE (1966–February 2007) and International Pharmaceutical 
Abstracts (1970–February 2007) was performed using the search terms anthracyclines and extravasation.  
DATA SYNTHESIS: Extravasation of anthracyclines can have devastating effects. After infiltration of 
these drugs into the interstitial tissue, damage may range from mild erythema and pain to severe tissue 
necrosis. Many agents have been studied in the management of these injuries; however, few have 
demonstrated efficacy and treatment remains controversial. Nonpharmacologic modalities shown to limit 
extravasation injuries include local tissue cooling and elevation of the affected area. Corticosteroids, 
sodium bicarbonate, hyaluronidase, hyperbaric oxygen, heparin fractions, α-tocopherol, N-acetylcysteine, 
and granulocyte macrophage-colony stimulating factor have all either been shown to be ineffective or 
have limited data supporting their use. Topical dimethyl sulfoxide (DMSO) has been shown in 
prospective studies to limit the course of extravasation injuries. Dexrazoxane has been shown in animal 
models and case reports to be useful in the management of anthracycline extravasation. Two recent 
prospective clinical trials examining intravenous dexrazoxane 1000 mg/m2 within 6 hours of 
extravasation, 1000 mg/m2 24 hours after extravasation, and 500 mg/m2 48 hours after extravasation 
injuries add to the data supporting the use of this agent in such injuries. Of the 54 patients enrolled, 
surgery-requiring necrosis was avoided in 98.2%.  
CONCLUSIONS: The optimal treatment of anthracycline extravasation includes local tissue cooling, 
elevation of the afflicted extremity, dexrazoxane administration, and possibly topical DMSO. Many other 
drugs have been investigated; however, due to a lack of data, they cannot be recommended for the 
management of anthracycline extravasation.  
 
 
 
 
 
 
 
 
 
Request 
What is the optimal treatment for anthracycline extravasation? 
Response 
BACKGROUND 
Extravasation is a devastating complication that can develop when a drug infiltrates the interstitial 
tissue surrounding the blood vessel. It can occur with any intravenously administered drug; 
however, damage caused by some chemotherapeutic agents is particularly serious. Injury due to 
extravasation has been reported to be responsible for 0.5–6% of adverse effects related to 
chemotherapy administration.1 Those particularly harmful when extravasated include the 
anthracyclines (doxorubicin, daunorubicin, epirubicin, idarubicin), and treatment of such a 
complication due to these agents remains controversial.  
The severity of tissue damage due to anthracycline extravasation is proportional to the amount and 
concentration of drug that has infiltrated the interstitial tissue.2,3 The extent of damage can range 
from mild erythema, edema, and pain to severe tissue necrosis and ulceration involving underlying 
structures such as the extensor tendons of the hand. Ulceration may not present for weeks, which 
is consistent with the mechanism of tissue injury caused by anthracyclines. Once these agents 
infiltrate the tissue, they complex with DNA as an extension of their antitumor mechanism of 
action and cause cell death. After the dying cells lyse, the anthracyclines are released and are able 
to interact with additional cells, leading to a vicious cycle of tissue damage.1–3 Doxorubicin has 
been shown to be present in the area of extravasation for up to 5 months after the incident.4 This 
prolonged retention leads to continuing damage and prolongs healing time.  
Use of an antidote for such injuries would be ideal; however, evidence supporting any one method 
of managing anthracycline extravasation is limited. This lack of evidence is due partly to the rarity 
of occurrences, as well as the complicated, urgent nature of the injury, which makes it difficult to 
investigate in large, prospective, randomized studies. Unlike anthracycline-induced 
cardiomyopathy, literature addressing anthracycline extravasation management is limited to 
animal studies, case reports, and small human studies. Some of the therapeutic modalities 
investigated for the management of anthracycline extravasation include tissue cooling and 
elevation of the affected area, surgical debridement and reconstruction, injected and topical 
cortico-steroids, sodium bicarbonate, hyaluronidase, hyperbaric oxygen, heparin fractions, α-
tocopherol, N-acetylcysteine, granulocyte macrophage-colony stimulating factor (GM-CSF), 
dimethyl sulfoxide (DMSO), and dexrazoxane. The majority of human data in anthracycline 
extravasation includes the use of DMSO and dexrazoxane (Table 1).5–13 
LITERATURE REVIEW 
A search of MEDLINE (1966—February 2007) and International Pharmaceutical Abstracts 
(1970—February 2007) was performed using the search terms anthracyclines and extravasation. 
Review articles, clinical trials, animal studies, and case reports were identified, and references of 
these articles were reviewed for additional reports. Articles most pertinent to the treatment of 
anthracy-cline extravasation are reviewed here.  
 
To prevent anthracycline extravasation, drug administration through a central line, when possible, 
and ensuring good blood return prior to administration are of utmost importance. Moreover, the 
use of liposomal doxorubicin has been shown to cause only mild extravasation reactions. In a 
report of 8 extravasations of liposomal doxorubicin, patients developed transient, mild irritation at 
the infusion site that resolved after removal of the catheter, elevation of the extremity, and 
application of ice.14 Nevertheless, the anthracycline infusion should be stopped at the first sign of 
extravasation. Cooling the site has been studied and is advocated in the product labeling of 
idarubicin15 and doxorubicin.16 In a series of 50 patients treated with intermittent ice for 3 days 
after extravasation of an antitumor agent, only 12 (24%) required surgical intervention.17 
Additionally, product labeling recommends elevation of the involved extremity.  
Pharmacologic approaches to treatment of extravasation have demonstrated varying response 
rates; many have fallen out of favor. Sodium bicarbonate administered locally to increase tissue 
pH and therefore decrease pH-dependent interactions of anthracyclines with cell components has 
been shown to be of no benefit. In fact, local administration of sodium bicarbonate itself is 
associated with tissue damage.1,2 Likewise, the use of glucocorticoids have fallen out of favor due 
to the relative absence of inflammatory mediators in the afflicted area.1–3 
Additional agents have been studied; however, many have limited data supporting their use. 
Hyaluronidase breaks down hyaluronic acid, allowing increased absorption of anthracyclines.18 
Moreover, heparin fractions are believed to have beneficial effects in anthracycline extravasation 
by binding anthracycline, inhibiting coagulation, and promoting the formation of new 
vasculature.19 In rat models, those receiving both subcutaneous hyaluronidase and heparin 
fractions had significantly smaller ulcers compared with controls.18,19 Hyperbaric oxygen has also 
been studied in the management of anthracycline extravasation. Conflicting results from 2 animal 
studies (1 showing potentiation of cytotoxicity; 1 showing beneficial effects) limit the use of this 
treatment modality.4 N-acetylcysteine has been shown to be of no benefit in treating anthracycline 
extravasations.1 GM-CSF has been shown to accelerate wound healing, promote cellular adhesion, 
and cause fibroblasts to have a more differentiated state. However, few cases describing the 
successful use of GM-CSF have been reported.10 Due to a lack of clinical trial data, use of these 
agents cannot be recommended.  
Successful outcomes have been noted with the use of topical DMSO. Case reports and prospective 
studies demonstrate that this agent can limit the course of the tissue injury caused by anthracycline 
extravasation.5–7,20–22 In these reports, use of a 90–99% topical DMSO solution was described. For 
the treatment of anthracycline extravasation, DMSO is believed to work by acting as a free radical 
scavenger and by increasing systemic absorption of the extravasated drug.1 In an early animal 
study (mouse model) evaluating the combination of DMSO and vitamin E (tocopheryl salts) for 
the treatment of doxorubicin extravasation, investigators found that DMSO plus vitamin E did not 
reduce ulceration.21 Reports23,24 in other animals have been favorable; it is not understood why 
there was a lack of response in this mouse model.21 
A prospective study was conducted in patients with either doxorubicin or daunorubicin 
extravasation.5 DMSO was applied topically and allowed to air dry. Median time to DMSO 
application after extravasation was 25 minutes, and none of the patients developed ulcerations or 
required surgery. Severe blistering did occur in one patient who had DMSO applied under a 
bandage. In a similar prospective study of 144 patients who experienced extravasation with 
doxorubicin, epirubicin, mitomycin, mitoxantrone, cisplatin, carboplatin, ifosfamide, or 
fluorouracil, the effect of DMSO was investigated.6 Forty of the 68 patients who received 
doxorubicin, epirubicin, or mitomycin had complete resolution of symptoms by the end of one 
week. Mild local burning was associated with DMSO application in this study. In another 
prospective study, the effects of DMSO in combination with α-tocopherol were investigated for 
the treatment of extravasation after administration of an anthracycline or mitomycin.7 None of the 
patients developed ulceration, and the only adverse effects noted were local skin irritation and 
blisters in 2 patients. Based on the results of these studies, some clinicians recommend the use of 
DMSO in conjunction with immediate cessation of anthracycline infusion and application of 
ice.1,2,4 
Dexrazoxane has a Food and Drug Administration (FDA)—approved indication for use in 
reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration 
to women with metastatic breast cancer. In addition, recent data support its potential role in the 
treatment of anthracycline extravasation. After intravenous administration, dexrazoxane is 
metabolized intracellularly to ADR-925, which binds free iron and removes iron from the iron— 
doxorubicin complex, thereby preventing formation of free radicals.25 Interactions between 
anthracyclines and topoisomerase are also inhibited by dexrazoxane preventing the DNA-cleaving 
activity of these agents.25 Three animal studies have examined the use of dexrazoxane in mice.26–
28 In all 3 studies, injuries caused by subcutaneous anthracycline administration were reduced by 
intraperitoneal or intravenous dexrazoxane.  
In addition to the aforementioned animal studies, dexrazoxane use for the treatment of 
extravasation was described in 7 patients (Table 1).8–12 Three patients had extravasation with 
epirubicin and 4 with doxorubicin. Dosage schedules and other supportive therapies varied among 
the cases. Overall, injury due to extravasation was limited by administration of dexrazoxane. Three 
patients did not experience necrosis and 6 patients were able to avoid surgery.8,9,11,12 Adverse 
reactions reported included pain during dexrazoxane infusion, transient increases in results of liver 
function tests, and leukopenia.9,11 
Most recently, the results of 2 international studies were reported.13 Both were European 
multicenter, open-label, single-arm trials. Patients (N = 17 and N = 36) were included if they had 
developed anthracycline (ie, epirubicin, doxorubicin, or daunorubicin) extravasation proven by 
fluorescence-positive tissue biopsy. The majority of patients were female, and the mean age was 
55 years. Participants in both studies were allowed to receive localized cooling; topical treatment 
with DMSO or steroids was not allowed. All patients received intravenous dexrazoxane 1000 
mg/m2 within 6 hours after extravasation, 1000 mg/m2 24 hours after extravasation, and 500 mg/m2 
48 hours after extravasation. The primary endpoint of both studies was prevention of surgery-
requiring necrosis.  
All of the patients in the first study avoided surgery; one patient in the second study required 
surgery. Additionally, 71% of the patients continued their scheduled chemotherapy regimen 
without postponement. Overall, patients experienced only mild sequelae including sensory 
disturbances, skin atrophy, pain, disfigurement, and limitation of movement. Toxicities with the 
administration of dexrazoxane were mild. In the first study, 60.8% experienced injection site 
reactions; after unspecified buffer changes in the second study, injection site reactions were 
reduced to 14%. Wound infections, nausea, and vomiting occurred in 10.0%, 18.8%, and 7.5% of 
the participants, respectively. Hematologic toxicities were demonstrated in this study; however, it 
was unclear whether these were caused by the study drug or chemotherapy. Although these studies 
were small, their results significantly add to existing data supporting the use of dexrazoxane in 
anthracycline extravasation.13 
Based on animal studies, case reports, and 2 prospective Phase II/III trials, dexrazoxane is a 
promising agent for the treatment of anthracycline extravasation. Currently, dexrazoxane is 
available in the US in 250- and 500-mg vials and is approved for prophylaxis of anthracycline-
induced cardiomyopathy. TopoTarget (Denmark) is seeking licensure of dexrazoxane for the 
treatment of anthracycline extravasation and was granted orphan drug status by the FDA in 2004. 
Doses used in the studies of dexrazoxane in anthracycline extravasation differ from those used in 
the prevention of cardiomyopathy. For the prevention of cardiomyopathy, the drug is dosed in a 
10:1 ratio (eg, dexrazoxane 500 mg/m2: doxorubicin 50 mg/m2). All doses reported in humans for 
the treatment of anthracycline extravasation were fixed, ranging from 500 mg/m2 to 1500 mg/m2.  
Adverse effects associated with the use of dexrazoxane in anthracycline extravasation were mild 
in the 2 recently reported clinical trials and included injection site reactions, wound infections, 
nausea, and vomiting.13 However, tissue necrosis was attributed to the use of dexrazoxane in one 
case report in which the patient was receiving cyclophosphamide, doxorubicin, vincristine, and 
prednisone (CHOP) in addition to dexrazoxane for the treatment of non-Hodgkin's lymphoma.29 
During the dexrazoxane infusion, the patient experienced pain at the infusion site without evidence 
of extravasation and subsequently developed tissue necrosis necessitating recurrent skin grafts.  
Summary 
Many agents have been investigated for use in anthracy-cline extravasation, yet results have not 
shown effectiveness. Tissue cooling has been shown to be moderately effective and is 
recommended in the product labeling of doxorubicin and idarubicin. Until recently, DMSO has 
shown the most promising results in anthracycline extravasation. The latest agent to be 
investigated, dexrazoxane, has shown efficacy in animal studies, case reports, and prospective 
studies. Despite the limited nature of these reports, dexrazoxane appears to be a promising agent 
for the treatment of anthracycline extravasation. Based on available literature, the optimal 
treatment of anthracycline extravasation includes a combination of ice application, elevation of the 
extremity, dexrazoxane administration, and possibly DMSO. Lack of evidence supporting use of 
the additional agents discussed here limits their use. 
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